Despite a recent 4.9% weekly pullback, shareholders of German-listed CHAPTERS Group (ETR:CHG) have seen staggering total returns exceeding 900% since 2019, fueled by explosive revenue growth. The journey highlights the potential rewards—and risks—of investing in high-growth, pre-profit companies.
As the STOXX Europe 600 grapples with volatility, some investors are turning their gaze to smaller, often overlooked companies. We examine three European penny stocks, each with a market capitalization exceeding €10 million, assessing their potential amidst a challenging macroeconomic backdrop.
Gold prices have surged past $5,500, driven by geopolitical tensions and fiscal fears. Yet, analysts caution that its reputation as a stable store of value may be overstated, pointing to inherent volatility and shifting market dynamics.
London-listed mineral sands explorer Capital Metals (LON: CMET) is projected to reach breakeven within two years, with analysts forecasting a first profit in 2028. The debt-free company's path hinges on achieving a steep annual growth rate amid its investment phase in UK and Sri Lankan projects.
A new financial analysis suggests shares of UK property services group LSL could be trading at a significant discount to their estimated intrinsic value, presenting a potential opportunity for investors.
Annaly Capital Management capped off a robust 2025 with a fourth-quarter economic return of 8.6%, driven by a constructive fixed-income environment and growth across its core strategies. The mortgage REIT highlighted conservative leverage, a secure dividend, and strategic capital deployment as it navigates evolving market conditions.
Altria Group reported adjusted earnings growth and robust shareholder returns for 2025, even as it grapples with a rapidly transforming nicotine market dominated by illicit flavored vapes and intense competition in oral tobacco.
Amidst a backdrop of geopolitical tensions and market volatility, a closer look reveals resilient European companies whose current share prices may not reflect their underlying strength and future growth prospects.
While European indices face pressure, underlying business optimism is at a 20-month high. We spotlight three under-the-radar companies—Premier Energy, BW Offshore, and RVRC Holding—whose fundamentals suggest they are well-positioned to navigate the current climate and deliver value.
As markets swing between hype and fundamentals, Royal KPN's consistent earnings growth and prudent governance present a compelling case for stability-focused investors in the telecom sector.
Bitcoin's struggle to hold the $90,000 level intensifies as a massive monthly options expiry approaches, driving traders toward defensive positioning and heightened volatility hedging.
UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.
A new discounted cash flow analysis indicates Corero Network Security plc (LON:CNS) may be significantly undervalued at current trading levels, presenting a potential opportunity for investors in the cybersecurity sector.
Despite record iPhone demand, Apple CEO Tim Cook warns that soaring memory chip costs are set to squeeze margins, highlighting a supply crisis gripping the entire tech industry.
PennyMac Mortgage Investment Trust (PMT) reported a robust fourth quarter, highlighted by a 13% return on equity and strategic advancements in its securitization business. Executives outlined a confident outlook for 2026, emphasizing disciplined risk management and growth in targeted lending segments.
The medical technology giant reports double-digit organic sales growth for the fourth consecutive year, driven by its Mako robotic system and strategic leadership shifts, while navigating tariffs and a shifting competitive landscape.
Facing a tough freight environment, Schneider National's leadership outlines a strategy centered on cost discipline, tech investment, and strategic positioning in intermodal and dedicated services to steer toward future profitability.
MaxLinear Inc. reported a 48% year-over-year revenue jump for Q4 2025, powered by its infrastructure business, even as it manages a near-term dip in broadband and intensifying competition in key markets.
